Pasteurized Akkermansia muciniphila attenuates high-fat diet-induced bone loss via Nr4a1-dependent Treg differentiation — murine preclinical study
In high-fat diet-induced obese mice, pasteurized (but not live) Akkermansia muciniphila reduced trabecular bone loss and inhibited osteoclastogenesis through an intestinal Nr4a1/Treg axis.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Trabecular bone microarchitecture (μCT) | D | ▲ Favorable | reversão da perda trabecular HFD; valores absolutos não reportados | 1 |
| Bone formation marker (serum P1NP) | D | ▲ Favorable | aumento vs. controle HFD; magnitude numérica não reportada | 1 |
| Bone resorption marker (serum β-CTX) | D | ▲ Favorable | redução vs. controle HFD; magnitude numérica não reportada | 1 |
| Intestinal Treg cell differentiation (CD4+CD25+Foxp3+) | D | ▲ Favorable | expansão por pAkk via CD103+ DCs; valores absolutos não reportados | 1 |
| Nr4a1 expression and mechanistic dependence (KO mice) | D | ▲ Favorable | Nr4a1 KO aboliu completamente o efeito protetor de pAkk | 1 |
| In vitro osteoclastogenesis inhibition by pAkk-induced Tregs | D | ▲ Favorable | supressão confirmada em cocultivo; magnitude não reportada | 1 |
| Effect of live Akk vs. pAkk on bone loss | D | — Neutral | Akk viva não demonstrou efeito protetor ósseo significativo neste modelo | 1 |
Context
Obesity-associated bone loss is linked to gut microbiota dysbiosis and reduced Akkermansia muciniphila abundance. Postbiotics derived from pasteurized bacteria offer greater pharmacological stability than live forms. The immunological mechanism connecting gut microbiota to bone remodeling remained unclear.
What the study showed
pAkk reversed HFD-induced trabecular bone loss (absolute μCT values not reported in available abstract), increased P1NP, and decreased β-CTX versus HFD control. pAkk expanded intestinal and splenic Treg populations via CD103+ dendritic cells. Nr4a1 knockout completely abrogated pAkk's bone-protective effects. Live Akk did not replicate these outcomes, functionally distinguishing the two forms.
How it was done
In vivo experimental study in C57BL/6 mice with HFD; 4-week gavage with pAkk, live Akk, or control. Bone assessment by μCT and histomorphometry; serum markers by ELISA; immune phenotyping by flow cytometry and immunofluorescence; RNA-seq for key gene identification; mechanistic validation with Nr4a1 KO mice; cell coculture to confirm Treg-mediated osteoclastogenesis suppression. Fecal microbiota transplantation (FMT) used to establish causal role of gut microbiota.
Effect magnitude
Absolute values and 95% CI were not reported in the available text; effect direction consistently favors pAkk over HFD control across all bone and immune outcomes. Nr4a1 knockout fully abolished the protective effect, indicating complete mechanistic dependence in this model.
Limitations
Exclusively preclinical (murine) study; no human data prevent any direct clinical extrapolation. Per-group sample size not specified in the abstract. No formal risk-of-bias tool reported (animal studies typically assessed with SYRCLE RoB Tool — not mentioned). The Nr4a1/Treg mechanism is validated only in the HFD murine obesity model, not in other bone loss contexts (aging, menopause, glucocorticoids). Active components of pAkk responsible for Nr4a1 activation remain unidentified.
In clinical practice
This study does not support any clinical recommendation for pAkk in human bone loss. Clinicians should treat these findings as a preclinical mechanistic hypothesis. The functional difference between live and pasteurized Akk is relevant for designing future clinical trials.
What is still missing
Clinical trials in humans with obesity and low bone mass are required to determine whether pAkk activates the Nr4a1/Treg axis and produces measurable bone effects. Identification of the structural components of pAkk responsible for Nr4a1 activation is a mandatory intermediate step.